(Hypertension. 2000;35:1284.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
Angiotensin I–Converting Enzyme Isoforms (High and Low Molecular Weight) in Urine of Premature and Full-Term Infants
From the Departamento de Medicina, Disciplina de Nefrologia (M.A.H., D.E.C.); Departamento de Pediatria, Disciplina de Nefropediatria (G.L.D.B.) and Departamento de Biofísica (A.K.C.), Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil.
Correspondence to Dr Dulce Elena Casarini, Universidade Federal de São Paulo, Escola Paulista de Medicina, Depto de Medicina, Disciplina de Nefrologia, Rua Botucatu 740, CEP 04023–900, São Paulo, SP, Brazil. E-mail dulce{at}nefro.epm.br
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—Angiotensin I–converting enzyme (ACE) isoforms in urine from healthy and mildly hypertensive untreated patients have been described in the literature. Healthy subjects have high- and low-molecular-weight ACEs (170 and 65 kDa), whereas mildly hypertensive untreated patients have only low-molecular-weight ACEs (90 and 65 kDa), both of which resemble ACE from the N-terminal domain. Previous studies have shown that ACE is regulated during development, and renal tubules of premature human infants are not completely mature, given that nephrogenesis is not complete until the 36th week of gestation. The aim of the present study was to purify and characterize ACE isoforms from urine of premature and full-term infants and to detect the presence of the N-domain form of ACE during prenatal development. Urine from premature and full-term infants was concentrated in an Amicon concentrator, dialyzed in the same equipment against 50 mmol/L Tris-HCl buffer (pH 8.0) that contained 150 mmol/L NaCl, and submitted to gel filtration on an AcA-34 column equilibrated with the buffer described above. Two peaks (P1 and P2 for premature infants; TP1 and TP2 for full-term infants) with ACE activity on hippuryl-His-Leu (Km, 3 mmol/L) were detected. All enzymes were Cl- dependent and inhibited by captopril and EDTA. The peptides angiotensin-(1-7) and N-acetyl-Ser-Asp-Lys-Pro, described as specific for N-domain ACE, were hydrolyzed by P2 and TP2, which suggests that both enzymes are N-domain ACE. In premature infants, P1 activity with hippuryl-His-Leu was 12-fold lower than P2 activity, but in full-term infants, the difference between TP1 and TP2 was 1.6-fold. Chromatography profiles of urine from premature infants were analyzed on days 1, 3, 7, 14, 21, and 30 after birth. The P1 of ACE was detected around the 21st and 30th days, whereas P2 was detected from day 1. These results suggest that ACE activity is related to renal development and that N-domain ACE as well as full-length ACE is present in urine from premature infants. This may indicate that healthy subjects produce and secrete the N-domain form of ACE even before term development.
Key Words: infants, premature • infants, full-term • angiotensin-converting enzyme • urine • nephrogenesis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Angiotensin I–converting enzyme (ACE; peptidyl dipeptidase A, kininase II, endopeptidase EC 3.4.15.1) is a transmembrane zinc metallopeptidase that plays an important role in cardiovascular homeostasis and also a physiological role in blood-pressure regulation and water and salt metabolism through its action on angiotensin I (Ang I) and bradykinin.1 ACE can hydrolyze other peptides in vitro by acting either as a dipeptidyl carboxypeptidase or an endopeptidase, by cleaving terminal tripeptides.2 The enzyme may also be involved in vivo in the metabolism of substance P3 in some areas of the brain and the blood-vessel wall.
ACE is widely distributed in the organism, in
endothelial, epithelial, neuroepithelial, and
mononuclear cells and in body fluids such as urine, cerebrospinal
fluid, and amniotic fluid.4 5 6 7 Human ACE takes 2 forms:
somatic ACE, with a molecular weight (MW) between 150 and 180 kDa,
which has 2 homologous domains, each of which contains a zinc-binding
site and an active center,8 and a low-molecular-weight
(LMW) form of 90 to 100 kDa found in testis,7 which
contains only the C-domain. Some authors have demonstrated the
existence of N-terminal domain (N-domain) ACE in body fluids. Deddish
et al9 purified and characterized in ileal fluid collected
after surgery a naturally occurring short form of ACE that had only the
N-domain active site of ACE. Casarini et al5 isolated and
characterized 2 forms of ACE in human urine, a high-molecular-weight
(HMW) form of 
170 kDa and a LMW form of 65 kDa (N-domain ACE).
The renin-angiotensin system (RAS) is an important regulator of cardiovascular diseases and systemic blood pressure. Recently, the potential importance of a local RAS that acts independently from systemic actions of the endocrine RAS has been described in various tissues.10 The kidney is the richest source of ACE in human.11 The function of ACE in the kidney is related to the conversion of Ang I to Ang II in the glomerular and peritubular circulation. The proximal tubular cells express mRNA and protein for angiotensinogen, renin, and ACE.12 13 In addition to full-length ACE, N-domain ACE (such as the somatic enzyme) also is found in mesangial cells.14 ACE is present at high levels on the brush border of the proximal tubule as well as in the vascular endothelial cells.7 ACE in the brush border of the proximal tubule and glomerulus is probably involved in the local metabolism of peptides, especially in the production of Ang II in the tubule and tubular lumen, which is present here at high levels and is probably involved in sodium reabsorption.15
Although extensive studies have been performed in cultured endothelial cells,16 17 the regulation of ACE synthesis in vivo is largely unknown. In the rat, ACE concentration in kidney microsomes increases during the first 2 weeks of life and then declines to reach low values at the end of the first month.18 Kidney development is incomplete at birth in rats, with maturation occurring during the third postnatal week after an increase in renal mass. Yosipiv et al19 reported that ACE activity is present in the developing kidney and that synthesis from precursor mRNA is the likely source of renal ACE activity.
Human plasma ACE levels are high during infancy and decrease to stable values during adult life. The reason for this fact is unknown, as is the ontogeny of ACE gene expression and tissue levels.20
On the basis of the fact that the kidney reaches maturity at the 36th week of human gestation and that human urine and mesangial cells have N-domain ACE,5 14 the aim of the present study was to purify and characterize the ACEs from urine of premature and full-term infants to detect the presence of the N-domain form of ACE. We also studied the ACE isoform activity profile in postnatal evolution to verify whether nephrogenesis could influence the secretion of ACE.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Purification of ACE
Urine Collection
The parents of healthy, premature (n=15; 1500 g and gestational age of 30 weeks) and full-term infants (n=15) approved the protocol after reading about the project. The protocol was approved by the Ethics Committee on Human Experimentation (Hospital São Paulo/Universidade Federal de São Paulo). All urine was collected from children with normal renal function (assessed by creatinine clearance).
Urine Preparation
Urine was collected from premature and full-term infants, pooled,
concentrated in an Amicon concentrator, and dialyzed in the same
equipment against 50 mmol/L Tris/HCl buffer, pH 8.0, that
containing 150 mmol/L NaCl. Urine from premature infants was also
collected on days 1, 3, 7, 14, 21, and 30 after birth. Urine samples
were treated as described above.
Gel-Filtration Chromatography on an AcA-34
Column
Concentrated and dialyzed urine was submitted to gel filtration on
an ultrogel AcA-34 column (1.5x108 cm; Sigma Chemical Co)
equilibrated with 50 mmol/L Tris/HCl buffer (pH 8.0) that
contained 150 mmol/L NaCl and was eluted with the same buffer at a
flow rate of 20 mL/h. Fractions of the gel-filtration column were
monitored by absorbance measurements at 280 nm and for ACE activity by
use of hippuryl-His-Leu (HHL) as substrate.
Protein Determination
Protein concentration was determined by the method of
Bradford21 (BioRad protein assay) with bovine serum
albumin as standard, except when absorbance at 280 nm was used
for the chromatographic elution profile.
Enzymatic Activity Assay
ACE catalytic activity was determined fluorometrically by the
method of Friedland and Silverstein.22 The enzyme was
incubated with 200 µL of assay solution that included 5 mmol/L
HHL in 100 mmol/L potassium buffer (pH 8.3) that contained
300 mmol/L NaCl and 10-4 mol/L
ZnSO4 for 3 hours at 37°C. The enzymatic
reaction was stopped by the addition of 1.5 mL of 0.28N NaOH, 100 µL
of o-phthaldialdehyde (20 mg/mL) in methanol was added and the
fluorescent reaction was stopped by the addition of 200 µL of
3N HCl. The product, L-His-Leu, was measured
fluorometrically (360 nm excitation and 500 nm emission) by use of an
Aminco fluorometer.
Characterization of ACE
Kinetic Parameters
Enzymatic activities of the different ACEs were determined as
described above, by measurement of initial velocity of product
formation with HHL as substrate at concentrations that ranged from 0.25
to 5 mmol/L. Data were plotted according to the Lineweaver-Burk
equation and analyzed by the Grafit program.23
Influence of Chloride on ACE Activity
The influence of chloride on ACE activity was determined with
5 mmol/L HHL as substrate in standard buffer, in which NaCl
concentration ranged from 50 to 400 mmol/L. The activity was
measured as described above.
Inhibitor Studies
Captopril and EDTA were used as inhibitors. Enzymes
were preincubated with inhibitor for 30 minutes at 37°C
before addition of the substrate (5 mmol/L HHL). Under these
conditions, the assay was developed as described above. The
inhibitor concentration in the final mixture was 2.5
µmol/L captopril and 10 µmol/L EDTA.
Determination of Optimum pH
Optimum pH was determined by use of 5 mmol/L HHL diluted in
the following buffers that contained 300 mmol/L NaCl (in
mmol/L): sodium acetate buffer 125 (pH 5.0 and 5.5), sodium phosphate
buffer 125 (pH 6.0 and 6.5), Tris/HCl buffer 125 (pH 7.0, 7.5, 8.0, and
8.5), and glycine/NaOH buffer 125 (pH 9.0 and 10.0). Activity was
measured as described above.
SDS-PAGE and Western Blot Analysis
PAGE in the presence of SDS was performed on a 7.5% slab gel
according to the method of Laemmli24 with 10 µg of
denatured and reduced protein. Proteins were stained with the BioRad
Silver Stain Plus kit. Protein standards (all from BioRad) used were
myosin (MW, 205 kDa), ß-galactosidase (116 kDa),
phosphorylase b (97.4 kDa), bovine albumin (66
kDa), egg albumin (45 kDa), and carbonic anhydrase (29
kDa).
Electrophoretic transfer was performed for 90 minutes at constant voltage (90 V) with a transfer membrane (polyvinylidene fluoride membrane micropore; BioRad) and transfer buffer (15 mmol/L Tris, 190 mmol/L glycine, and 0.1% SDS). The membrane was incubated in 0.1 mol/L PBS that contained 3 mg/mL BSA for 1 hour before overnight incubation at 4°C with the monoclonal antibodies 9B9, 5F1 (diluted 1:250; gift from Dr Sergei Danilov, University of Illinois of Chicago), and the polyclonal antibody Y1 against ACE (diluted 1:250; gift from Dr François Alhenc-Gelas, INSERM, Paris, France). Subsequent steps were performed with the biotin/streptavidin system (Amersham) as recommended by the manufacturer.
Hydrolysis of Ang-(1-7) and
N-acetyl-Ser-Asp-Lys-Pro
The hydrolysis of Ang-(1-7) and
N-Acetyl-Ser-Asp-Lys-Pro peptides by the ACE enzymes was
assayed by high-performance liquid
chromatography. An aliquot of the samples was incubated
with Ang-(1-7) (10 µg) in 100 mmol/L phosphate buffer (pH 7.5)
that contained NaCl 150 mmol/L and
N-acetyl-Ser-Asp-Lys-Pro (10 µg) in 50 mmol/L
Tris/HCl buffer (pH 8.0) at a final volume of 500 µL for 18 hours to
obtain total hydrolysis of peptides at 37°C. The reaction was stopped
by the addition of 10 µL of 10%
H3PO4. The hydrolysis
products were separated by high-performance liquid
chromatography by use of an Aquapore ODS 300 (7
µm; reverse-phase column) equilibrated with 0.1% phosphoric acid
that contained 5% acetonitrile (vol/vol). Peptides were separated by
initial isocratic elution for 5 minutes followed by a 20-minute linear
gradient of 5% to 35% (vol/vol) acetonitrile in 0.1% phosphoric acid
at 1.5 mL/min. Reaction products were detected by absorbance at 214
nm; AUFS, 0.02. Amounts of hydrolysis products formed were
estimated from peak areas by comparison to known standards.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Using gel-filtration chromatography on an ultrogel AcA-34 column, we separated 2 peaks of ACE activity from urine of both premature and full-term infants; each group had HMW and LMW(N-domain ACE) forms (Figure 1).
|
The enzymes from premature urine, denominated P1 and P2, were purified
3 and 20 times, respectively, with a specific activity of 4.8 and 29.5,
with HHL as substrate. In urine from full-term infants, TP1 and TP2
were purified 2-fold, with specific activity of 4.4 and 4.2,
respectively (Tables 1 and 2). The chromatographic
profile of urine from premature infants from the 1st to 30th day
demonstrated that peak 1 appears only around the 30th day after birth
(Figure 2).
|
|
|
The enzymes (P1, P2, TP1, and TP2) were found to be chloride dependent by use of HHL as substrate. The highest activity was found in 300 mmol/L NaCl, and the optimum pH for all enzymes was 8.0 with the same substrate.
Captopril inhibited P1 and P2 ACE activity from premature infants by 100% and 93%, respectively, and TP1 and TP2 ACE activities from term infants by 60%. The chelating agent, EDTA, inhibited 100% of P1, TP1, and TP2 activity and 92% of P2 activity.
Km values for all enzymes (P1, P2, TP1, and TP2) with HHL were calculated in millimoles per liter, and molecular mass, as determined by SDS-PAGE, was 170 kDa for P1 and TP1 of the HMW enzyme and 65 kDa for P2 and TP2 of the LMW enzymes (Figure 3).
|
Western blot analysis was performed with polyclonal antibody Y1 and monoclonal antibodies 9B9 and 5F1 against ACE N-domain. The purified ACE N-domains (P2 and TP2) were recognized by 9B9 and 5F1, as was the recombinant N-domain ACE used as a positive control. The negative control, recombinant C-domain ACE, did not bind with those antibodies (Figure 4). All enzymes (P1, P2, TP1, TP2, recombinant N-domain, and recombinant C-domain) were recognized by polyclonal antibody Y1.
|
The results of hydrolysis of Ang-(1-7) and N-acetyl-Ser-Asp-Lys-Pro, described being as specific substrates for N-domain ACE by P2 and TP2 ACE are given in Tables 3 and 4. The amounts of Ang-(1-7) and N-acetyl-Ser-Asp-Lys-Pro cleaved by the 2 enzymes and the C-domain ACE differed greatly, which suggests that P2 and TP2 are N-domain ACE.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present article is the first to describe ACE in urine of premature and full-term infants. We detected HMW and LMW forms of ACE enzyme in the infant urines. The present profile was similar to that of urine from adult subjects,5 with activity on HHL of P1 from premature infants differing from the peak 1 from term infants (TP1) by
7-fold. Molecular mass of 170 kDa for P1 and TP1 was similar to that of the somatic ACE forms, in which molecular mass ranges from 140 to 180 kDa.25 26 27 P2 and TP2 showed a molecular mass of 65 kDa, which was similar to the N-domain ACE (65 to 68 kDa) found in human urine5 and ileal fluid.28
All enzymes showed Cl- dependence similar to that of urinary ACE isoforms.5 HHL hydrolysis by ACEs (P1, P2, TP1, and TP2) was catalyzed more rapidly in the presence of 300 mmol/L Cl-, which differs from renal ACE, which shows maximal activation at 800 mmol/L, and ileal ACE, which shows maximal activation at 10 mmol/L Cl-.29 30 31
Optimum pH, with HHL as substrate, was 8.0 for P1, P2, TP1, and TP2 ACEs. In the literature, similar values are described for different ACEs with this substrate: pH 7.8 for ACE from human lung32 and pH 8.0 for urinary ACE from normal human subjects.4
Km values of enzymes P1, P2, TP1, and TP2 are calculated in millimoles per liter for HHL. In the literature, ACEs from human urine,4 lung,32 and kidney33 and from rabbit lung34 also have Km values calculated in millimoles per liter with HHL as substrate.
Captopril, a classical specific ACE inhibitor,33 35 inhibited P1, P2, TP1, and TP2 activities in a manner similar to the inhibition described in the literature for ACE from different sources.30 35 EDTA, the chelating agent, also inhibited all enzymatic activities.
Danilov et al36 described that monoclonal antibodies against ACE recognize at least 9 different epitopes, all located in the N-domain, and that monoclonal antibodies were not able to bind well to the C-domain. Urinary P2 and TP2 ACEs bound well to the monoclonal antibodies, as did N-domain ACE. We conclude that isoforms P2 and TP2 have characteristics similar to those of the N-domain and thus represent the active N-domain of the human ACE.
Ang-(1-7) is an active metabolite released by peptidases from Ang I or Ang II.37 Instead of being a vasoconstrictor, as is Ang II, Ang-(1-7) is a vasodilator on coronary arteries38 and exhibits potent natriuretic and diuretic actions in the kidney.39 40 In vitro, Ang-(1-7) is a substrate for ACE.41 Deddish et al42 demonstrated that Ang-(1-7) is cleaved to Ang1 2 3 4 5 and His-Pro by N-domain ACE 100 times faster than by C-domain ACE.42 Ang-(1-7) appears to be a relatively specific substrate for this domain. The present study showed that P2 and TP2 were able to hydrolyze this specific substrate better than P1 and TP1. ACE has recent been demonstrated to be both in vitro43 and in vivo (see reference 44 ) in the hydrolysis of N-acetyl-Ser-Asp-Lys-Pro. The peptide N-acetyl-Ser-Asp-Lys-Pro is also highly specific for N-domain ACE. Our results demonstrate that P2 and TP2 were also able to hydrolyze this peptide with a similar percentage of hydrolysis of recombinant N-domain. On the basis of the hydrolysis of Ang-(1-7) and N-acetyl-Ser-Asp-Lys-Pro, both substrates having been described as specific for N-domain ACE, we suggest that the enzymes P2 and TP2 are N-domain ACEs.
Nephrogenesis and tubular function are known to be incomplete in premature infants. Renal embryological development begins during the first week of gestation and continues until around the 36th week of gestation. Functional capacity, although not mature, begins around the 6th week of gestation. Infants that are born premature have underdeveloped structures and decreased renal function.45 Comparing the chromatographic profiles of urine from premature and full-term infants, we detected low activity of HMW ACE (P1) compared with LMW ACE (P2) in urine from premature infants. When the chromatographic profile of urine from premature infants was analyzed on different days, we detected the HMW P1 form of ACE around the 21st and 30th days after birth, whereas the P2 form of ACE (N-terminal) was present from the first day after birth. On the basis of the fact that morphological and physiological development of the kidney is incomplete at birth, we suggest that ACE expression follows a tissue-specific pattern of evolution during postnatal development. Costerousse et al18 reported that ACE concentration in the kidney microsomes followed the same pattern of evolution as the relative abundance of ACE mRNA, which increased during the first 2 weeks of life before declining and reaching a low value at the end of the first month. During the first 2 weeks after birth, a rapid increase in renal mass occurs that precedes the completion of renal morphogenesis in the third postnatal week.18 Our results demonstrated that until the third postnatal week, the level of HMW ACE (P1) was lower, perhaps because of brush-border differentiation and renal maturation. Further studies are necessary to understand this mechanism of enzyme production and liberation from the brush-border membrane of the kidney and also to determine whether posttranslational mechanisms could influence the release of ACE. In conclusion, our results suggest that, in addition to full-length ACE, N-domain ACE also is produced or secreted before birth, given that it is present at a premature age (day 1), and our results also suggest that ACE activity is related to renal development.
|
Acknowledgments |
|---|
This study was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (98/13696-1 and 99/01531-0) and the Conselho Nacional de Desenvolvimento Científico et Tecnológico.
Received November 3, 1999; first decision January 10, 2000; accepted January 14, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Yang HYY, Erdös EG, Levin V. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochem Biophys Acta. 1970;214:374–376.[Medline] [Order article via Infotrieve]
2. Skidgel RA, Erdös EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens [A]. 1987;A9:243–259. Review.
3. Skidgel RA, Engelbrench S, Johnson AR, Erdös EG. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides. 1984;5:769.[Medline] [Order article via Infotrieve]
4. Kokubo T, Kato I, Nishimura K, Hiwada K, Ueda E. Angiotensin converting enzyme in urine. Clin Chem Acta. 1978;89:375–379.[Medline] [Order article via Infotrieve]
5. Casarini DE, Carmona AK, Plavinik FL, Juliano L, Zanella MT, Ribeiro AB. Effects of calcium blockers as inhibitors of angiotensin I–converting enzyme. Hypertension. 1995;26(pt II):1145–1148.
6. Ryan JW, Oza MB, Martin LC, Pena GA. Components of the kallikrein-kinin system in urine. In: Fuji S, Moryia H, Suzuki T, eds. Kinins II: Biochemistry, Pathophysiology and Clinical Aspects. New York, NY: Plenum Press; 1978; 10: 313–323.
7.
Erdös EG. Angiotensin I-converting
enzyme and the changes in our concepts through the years.
Hypertension. 1990;16:363–370.
8. Bünning P, Riordan JF. Activation of angiotensin converting enzyme by monovalent anions. Biochemistry. 1983;22:110–116.[Medline] [Order article via Infotrieve]
9.
Deddish PA, Wang L, Jackman HL, Michel B, Wang J,
Skidgel RA, Erdös EG. Single domain angiotensin I
converting enzyme (kininase II): characteristics and properties.
J Pharmacol Exp Ther. 1996;279:1582–1589.
10. Dzau VJ. Tissue renin-angiotensin system: physiologic and pharmacologic implications: introduction. Circulation. 1988;77(pt 2):I1–I3.
11. Erdös EG, and Skidgel RA. The angiotensin I-converting enzyme. Lab Invest. 1987;56:345–348.[Medline] [Order article via Infotrieve]
12. Wolf G. Angiotensin as a renal growth promoting factor. Adv Exp Med Biol. 1995;377:225–236.[Medline] [Order article via Infotrieve]
13.
Casarini DE, Boim MA, Stella RCR, Krieger-Azzolini MH,
Krieger JE, Schor N. Angiotensin I-converting enzyme
activity in tubular fluid along the rat nephron. Am J
Physiol. 1997;272:F405–F409.
14. Andrade MC, Quinto BM, Carmona AK, Ribas OS, Boim MA, Schor N, Casarini DE. Purification and characterization of angiotensin I-converting enzymes from mesangial cells in culture. J Hypertens. 1998;16(pt 2):2063–2074.
15.
Braam B, Mitchell KD, Fox J, Navar LG. Proximal tubular
excretion of angiotensin II in rats. Am J
Physiol. 1993;264:F891–F898.
16. Ching SF, Hayes LW, Slakey LL. Angiotensin converting enzyme in cultured endothelial cells and growth medium: relationship to enzyme from kidney and plasma. Biochim Biophys Acta. 1981;657:222–231.[Medline] [Order article via Infotrieve]
17. Del Vecchio PJ, Smith JR. Expression of angiotensin-converting enzyme activity in cultured pulmonary artery endothelial cells. J Cell Physiol. 1981;108:337–345.[Medline] [Order article via Infotrieve]
18.
Costerousse O, Allegrini J, Huang H, Bounhik J,
Alhenc-Gelas F. Regulation of ACE gene expression and plasma levels
during rat postnatal development. Am J Physiol. 1994;267:E745–E753.
19.
Yosipiv IV, Dipp S, el-Dahr SS. Ontogeny of somatic
angiotensin-converting enzyme. Hypertension. 1994;23:369–374.
20. Cambien F, Alhenc-Gelas F, Herbeth B, Andre JL, Rokotovao R, Gonzales MF, Allegrini J, Bloch C. Familial resemblance of plasma angiotensin I-converting enzyme level: the Nancy study. Am J Hum Genet. 1988;43:774–780.[Medline] [Order article via Infotrieve]
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254.[Medline] [Order article via Infotrieve]
22. Friedland J, Silverstein E. A sensitive fluorometric assay for serum angiotensin converting enzyme. Am J Clin Pathol. 1976;66:416–424.[Medline] [Order article via Infotrieve]
23. Leatherbarrow RJ. Grafit version 3.0. Staines, UK: Erithacus Software Ltd.1992.
24. Laemmli UK. Cleavage of structure proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–685.[Medline] [Order article via Infotrieve]
25. Erdös EG, Skidgel RA. Structure and function of human angiotensin converting enzyme (kininase II). Biochem Soc Trans. 1985;13:42–44.[Medline] [Order article via Infotrieve]
26.
Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John
M, Tregear G, Corvol P. Two putative active centers in human
angiotensin I-converting enzyme revealed by molecular
cloning. Proc Natl Acad Sci U S A. 1988;85:9386–9390.
27. Hooper NM, Turner AJ. Isolation of two differentially glycosylated forms of peptidyl-dipeptidase A (angiotensin converting enzyme) from pig brain: a re-evaluation of their role in neuropeptide metabolism. Biochem Pharmacol. 1987;51:11–14.
28.
Deddish PA, Wang J, Michel B, Morris PW, Davidson NO,
Skidgel RA, Erdös EG. Naturally occurring active N-domain of
human angiotensin I-converting enzyme. Proc Natl Acad
Sci U S A. 1994;91:7807–7811.
29. Ehlers MRW, Kirsh RE. Catalysis of angiotensin I hydrolysis by human angiotensin-converting enzyme: effect of chloride and pH. Biochemistry. 1988;27:188–201.
30. Ehlers MRW, Riordan JF. Angiotensin I converting enzyme: Biochemistry and molecular biology. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology Diagnosis and Management. New York, NY: Raven Press; 1990:1217–1231.
31. Weare JÁ. Activation/inactivation of human ACE following chemical modifications of amino groups near the active site. Biochem Biophys Res Comm. 1982;104:1319–1326.[Medline] [Order article via Infotrieve]
32. Nishimura K, Yoshida N, Hiwada K, Ueda E, Kokubu T. Properties of three different forms of angiotensin I-converting enzyme from human lung. Biochem Biophys Acta. 1978;522:229–237.[Medline] [Order article via Infotrieve]
33.
Wei L, Alhenc-Gelas F, Corvol P, Clauser E. The two
homologous domains of human angiotensin I converting enzyme
are both catalytically active. J Biol Chem. 1991;266:9002–9008.
34. Iwata K, Blocher R, Soffer RL, Lai C-Y. Rabbit pulmonary angiotensin converting enzyme: the NH2 terminal fragment with enzymatic activity and its formation from the native enzyme by NH4OH. Arch Biochem Biophys. 1983;227:188–201.[Medline] [Order article via Infotrieve]
35.
Lanzillo JL, Stevens J, Dasarathy Y, Yotsumoto H,
Fanburg BL. Angiotensin I-converting enzyme from human
tissues. J Biol Chem. 1985;260:14938–14944.
36.
Danilov S, Jaspard E, Churakova T, Towbin H, Savoie F,
Wei L, Alhenc-Gelas F. Structure-function analysis of
angiotensin I-converting enzyme using monoclonal
antibodies. J Biol Chem. 1994;269:26806–26814.
37. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes; angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci. 1993;52:1461–1480.[Medline] [Order article via Infotrieve]
38. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27(pt 2):523–528.
39. DelliPizzi A, Hilchey SD, Bell-Quilley CP. Natriuretic action of angiotensin-(1-7). Br J Pharmacol. 1994;111:1–3.[Medline] [Order article via Infotrieve]
40.
Handa FK, Ferrario CM, Strandhoy JW. Renal actions of
angiotensin-(1–7): in vivo and in vitro studies.
Am J Physiol. 1996;270:F141–F147.
41. Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-(1–7) by angiotensin-converting enzyme. Hypertension. 1998;31(pt 2):362–367.
42.
Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA,
Erdos EG. N-domain specific substrate and C-domain
inhibitors of angiotensin I converting enzyme,
angiotensin 1–7 and keto-ACE. Hypertension. 1998;31:912–917.
43.
Rousseau A, Michaud A, Chauvet MT, Lenfand M, Corvol P.
The hemoregulatory peptide N-acetyl-Ser-Asp- Lys-Pro is a
natural and specific substrate of N-terminal active site of human
ACE. J Biol Chem. 1995;270:3656–3661.
44. Azizi M, Rousseau A, Ezan E, Guyene T-T, Michelet S, Grognet J-M, Lenfant M, Corvol P, Ménard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996;97:839–844.[Medline] [Order article via Infotrieve]
45. Bissinger RL. Renal physiology part 1: structure and function. Neonatal Network. 1995;14:9–20.
This article has been cited by other articles:
 |
|
 |
|
  M. C. Camargo de Andrade, G. S. Di Marco, V. de Paulo Castro Teixeira, R. A. Mortara, R. A. Sabatini, J. B. Pesquero, M. A. Boim, A. K. Carmona, N. Schor, and D. E. Casarini Expression and localization of N-domain ANG I-converting enzymes in mesangial cells in culture from spontaneously hypertensive rats Am J Physiol Renal Physiol, February 1, 2006; 290(2): F364 - F375. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||